WWOX gene is located in FRA16D, the highly affected chromosomal fragile site. Its tumor suppressor activity has been proposed on a basis of numerous genomic alterations reported in chromosome 16q23.3–24.1 locus. WWOX is affected in many cancers, showing as high as 80% loss of heterozygosity in breast tumors. Unlike most tumor suppressors impairing of both alleles of WWOX is very rare. Despite cellular and animal models information on a WWOX role in cancer tissue is limited and sometimes confusing. This review summarizes information on WWOX in human tumors.
EfeyanASerranoM. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle Georget Tex2007; 6: 1006–10.
2.
LiJPoiMJTsaiM-D. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry (Mosc)2011; 50: 5566–82.
3.
SpandidosDA. Oncogenes and tumor suppressor genes as paradigms in oncogenesis. J BUON2007; 12: S9–12.
4.
NarodSAFoulkesWD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer2004; 4: 665–76.
5.
Plaza-MenachoIMologniLMcDonaldNQ. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy. Cell Signal2014; 26: 1743–52.
6.
GreuberEKSmith-PearsonPWangJPendergastAM. Role of ABL family kinases in cancer: from leukaemia to solid tumors. Nat Rev Cancer2013; 13: 559–71.
7.
KaramouzisMVBadraFAPapavassiliouAG. Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol2007; 39: 851–6.
8.
BednarekAKLaflinKJDanielRLLiaoQHawkinsKAAldazCM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. Cancer Res2000; 60: 2140–5.
9.
HezovaREhrmannJKolarZ. WWOX, a new potential tumor suppressor gene. Biomed Pap Med Fac Univ Palacký Olomouc Czechoslov2007; 151: 11–5.
10.
GloverTW. Common fragile sites. Cancer Lett2006; 232: 4–12.
11.
WatanabeAHippoYTaniguchiHIwanariHYashiroMHirakawaKKodamaTAburatamiH. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res2003; 63: 8629–33.
12.
Ludes-MeyersJHKilHBednarekAKDrakeJBedfordMTAldazCM. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene2004; 23: 5049–55.
13.
AqeilanRIDonatiVPalamarchukATrapassoFKaouMPekarskyYSudolMCroceCM. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res2005; 65: 6764–72.
14.
Abu-OdehMBar-MagTHuangHKimTSalahZAbdeenSKSudolMReichmannDSidhuSKimPMAqeilanRI. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J Biol Chem2014; 289: 8865–80.
15.
AqeilanRIPekarskyYHerreroJJPalamarchukALetofskyJDruckTTrapassoFHanSYMelinoGHuebnerKCroceCM. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA2004; 101: 4401–6.
16.
AqeilanRIPalamarchukAWeigelRJHerreroJJPekarskyYCroceCM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res2004; 64: 8256–61.
17.
BouteilleNDriouchKHagePESinSFormstecherECamonisJLidereauRLallemandF. Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. Oncogene2009; 28: 2569–80.
18.
AqeilanRIHassanMQde BruinAHaganJPVoliniaSPalumboTHussainSLeeSHGaurTSteinGSLianJBCroceCM. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem2008; 283: 21629–39.
19.
AqeilanRIDonatiVGaudioENicolosoMSSundvallMKorhonenALundinJIsolaJSudolMJoensuuHCroceCMEleniusK. Association of Wwox with ErbB4 in breast cancer. Cancer Res2007; 67: 9330–6.
20.
Sałuda-GorgulASetaKNowakowskaMBednarekAK. WWOX oxidoreductase—substrate and enzymatic characterization. Z Für Naturforschung C J Biosci2011; 66: 73–82.
21.
NunezMILudes-MeyersJAldazCM. WWOX protein expression in normal human tissues. J Mol Histol2006; 37: 115–25.
22.
NunezMILudes-MeyersJAbbaMCKilHAbbeyNWPageRESahinAKlein-SzantoAJAldazCM. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat2005; 89: 99–105.
23.
GourleyCPaigeAJWTaylorKJWardCKuskeBZhangJSunMJanczarSHarrisonDJMuirMSmythJFGabraH. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res2009; 69: 4835–42.
24.
QinHRIliopoulosDNakamuraTCostineanSVoliniaSDruckTSunJOkumuraHHuebnerK. Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. Mol Cancer Res2007; 5: 957–65.
25.
AqeilanRIKurokiTPekarskyYAlbaghaOTrapassoFBaffaRHuebnerKEdmondsPCroceCM. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res2004; 10: 3053–8.
26.
LiY-PWuC-CChenW-THuangY-CChaiC-Y. The expression and significance of WWOX and β-catenin in hepatocellular carcinoma. Acta Pathol Microbiol Immunol Scand2013; 121: 120–6.
27.
LiJLiuJRenYYangJLiuP. Common chromosomal fragile site gene WWOX in metabolic disorders and tumors. Int J Biol Sci2014; 10: 142–8.
28.
GardenswartzAAqeilanRI. WW domain-containing oxidoreductase’s role in myriad cancers: clinical significance and future implications. Exp Biol Med Maywood NJ2014; 239: 253–63.
29.
YendamuriSKurokiTTrapassoFHenryACDumonKRHuebnerKWilliamsNNKaiserLRCroceCM. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res2003; 63: 878–81.
30.
JennerMWLeonePEWalkerBARossFMJohnsonDCGonzalezDChiecchioLDachs CabanasEDagradaGPNightingaleMProtheroeRKStockleyDElseMDickensNJCrossNCDaviesFEMorganGJ. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood2007; 110: 3291–300.
31.
MaedaNSembaSNakayamaSYanagiharaKYokozakiH. Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations. Virchows Arch Int J Pathol2010; 457: 423–32.
32.
LinJ-TTzaiT-SLiaoC-YWangJ-SWuTTWangH-YWuCHYuCCLuPJ. WWOX protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC. Ann Surg Oncol2013; 20: 193–9.
33.
CarterBSEwingCMWardWSTreigerBFAaldersTWSchalkenJAEpsteinJIIsaacsWB. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA1990; 87: 8751–5.
34.
ShengWWSoukupSBoveKGotwalsBLampkinB. Chromosome analysis of 31 Wilms’ tumors. Cancer Res1990; 50: 2786–93.
35.
ZhangWDHirohashiSTsudaHShimosatoYYokotaJTeradaMSugimuraT. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma. Jpn J Cancer Res1990; 81: 108–11.
36.
ChenTSahinAAldazCM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res1996; 56: 5605–9.
37.
PaigeAJTaylorKJStewartASgourosJGGabraHSellarGCSmythJFPorteousDJWatsonJE. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res2000; 60: 1690–7.
38.
IliopoulosDFabbriMDruckTQinHRHanS-YHuebnerK. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res Off J Am Assoc Cancer Res2007; 13: 268–74.
39.
PłuciennikEKusińskaRPotemskiPKubiakRKordekRBednarekAK. WWOX—the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol2006; 32: 153–7.
40.
GulerGHimmetogluCJimenezREGeyerSMWangWPCostineanSPilarskiRTMorrisonCSurenDLiuJChenJKamalJShapiroCLHuebnerK. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat2011; 129: 421–32.
41.
BalkoJMMillerTWMorrisonMMHutchinsonKYoungCRinehartCSánchezVJeeDPolyakKPratAPerouCMArteagaCLCookRS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci USA2012; 109: 221–6.
42.
LeeDYuMLeeEKimHYangYKimKPanniciaCKurieJMThreadgillDW. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest2009; 119: 2702–13.
43.
JullienNDieudonnéF-XHabelNMartyCModrowskiDPatinoALecandaFSévèreNMariePJ. ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo. Gene2013; 521: 55–61.
44.
ForemanPKGoreMKobelPAXuLYeeHHannumCHoHWangSMTranHVHorowitzMHorowitzLBhattRR. ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo. Mol Cancer Ther2012; 11: 1411–20.
45.
ArunBKilicGYenCFosterBYardleyDAGaynorRAshfagR. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomark Prev2005; 14: 1681–5.
46.
IliopoulosDGulerGHanS-YJohnstonDDruckTMcCorkellKAPalazzoJMcCuePABaffaRHuebnerK. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene2005; 24: 1625–33.
47.
BednarekAKKeck-WaggonerCLDanielRLLaflinKJBergsagelPLKiguchiKBrennerAJAldazCM. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res2001; 61: 8068–73.
48.
WangXChaoLJinGMaGZangYSunJ. Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumor Biol2009; 30: 8–14.
49.
ChangN-SSchultzLHsuL-JLewisJSuMSzeC-I. 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene2005; 24: 714–23.
50.
Göthlin EremoAWegmanPStålONordenskjöldBFornanderTWingrenS. Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients. Oncol Rep2013; 29: 1467–74.
51.
WangXChaoLMaGChenLZangYSunJ. The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype. J Cancer Res Clin Oncol2011; 137: 271–8.
52.
Yan H. Methylation status of WWOX gene promoter CpG islands in epithelial ovarian cancer and its clinical significance. Biomed Rep [Internet] 2013, http://www.spandidos-publications.com/10.3892/br.2013.86 (accessed 13 January 2014).
53.
NunezMIRosenDGLudes-MeyersJHAbbaMCKilHPageRKlein-SzantoAJGodwinAKLiuJMillsGBAldazCM. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer2005; 5: 64–64.
54.
XiongZHuSWangZ. Cloning of WWOX gene and its growth-inhibiting effects on ovarian cancer cells. J Huazhong Univ Sci Technol Med Sci2010; 30: 365–9.
55.
PaigeAJWZucknickMJanczarSPaulJMeinCATaylorKJStewartMGourleiCRichardsonSPerrenTGanesanTSSmythJFBrownRGabraH. WWOX tumor suppressor gene polymorphisms and ovarian cancer pathology and prognosis. Eur J Cancer Oxf Engl1990; 46: 818–25.
56.
YanHYuNTongJ. Effects of 5-Aza-2′-deoxycytidine on the methylation state and function of the WWOX gene in the HO-8910 ovarian cancer cell line. Oncol Lett2013; 6: 845–9.
57.
WeiSHBalchCPaikHHKimY-SBaldwinRLLiyanarachchiSLiLWangZWanJCDavuluriRVKarlanBYGiffordGBrownRKimSHuangTHNephewKP. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res2006; 12: 2788–94.
58.
LanCChenggangWYulanBXiaohuiDJunhuiZXiaoW. Aberrant expression of WWOX protein in epithelial ovarian cancer: a clinicopathologic and immunohistochemical study. Int J Gynecol Pathol2012; 31: 125–32.
59.
QinHRIliopoulosDSembaSFabbriMDruckTVoliniaSCroceCMMorrisonCDKleinRDHuebnerK. A role for the WWOX gene in prostate cancer. Cancer Res2006; 66: 6477–81.
60.
SuarezBKLinJBurmesterJKBromanKWWeberJLBanerjeeTKGoddardKAWitteJSElstonRCCatalonaWJ. A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet2000; 66: 933–44.
61.
LangeEMBeebe-DimmerJLRayAMZuhlkeKAEllisJWangYWaltersSCooneyKA. Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. Prostate2009; 69: 385–91.
62.
ChuangS-CLa VecchiaCBoffettaP. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett2009; 286: 9–14.
63.
LiuW-RShiY-HPengY-FFanJ. Epigenetics of hepatocellular carcinoma: a new horizon. Chin Med J (Engl)2012; 125: 2349–60.
64.
MorganTRMandayamSJamalMM. Alcohol and hepatocellular carcinoma. Gastroenterology2004; 127: S87–96.
Ruddon RW. Causes of cancer. Cancer biology. NY: Oxford University Press, 2007, pp.17–61.
67.
ParkS-WLudes-MeyersJZimonjicDBDurkinMEPopescuNCAldazCM. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer2004; 91: 753–9.
68.
HuB-STanJ-WZhuG-HWangD-FZhouXSunZ-Q. WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721. World J Gastroenterol2012; 18: 3020–6.
ThorgeirssonSSLeeJ-SGrishamJW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol2006; 44: 798–805.
71.
AdercaIMoserCDVeerasamyMBani-HaniAHBonilla-GuerreroRAhmedKShireACazanaveSCMontoyaDPMettlerTABurgartLJNagorneyDMThibodeauSNCunninghamJMLaiJPRobertsLR. The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol2008; 49: 373–83.
72.
RainussoNWangLLYusteinJT. The adolescent and young adult with cancer: state of the art—bone tumors. Curr Oncol Rep2013; 15: 296–307.
73.
SzuhaiKCleton-JansenA-MHogendoornPCWBovéeJVMG. Molecular pathology and its diagnostic use in bone tumors. Cancer Genet2012; 205: 193–204.
74.
OttavianiGJaffeNThe epidemiology of osteosarcoma. In: JaffeNBrulandOSBielackS (eds). Pediatric and adolescent osteosarcoma [Internet], Boston, MA: Springer US, 2009, pp. 3–13. http://www.springerlink.com/index/10.1007/978-1-4419-0284-9_1 (accessed 10 January 2014).
75.
TangNSongW-XLuoJHaydonRCHeT-C. Osteosarcoma development and stem cell differentiation. Clin Orthop2008; 466: 2114–30.
76.
KalraSGrimerRJSpoonerDCarterSRTillmanRMAbuduA. Radiation-induced sarcomas of bone: factors that affect outcome. J Bone Joint Surg Br2007; 89: 808–13.
77.
Le VuBde VathaireFShamsaldinAHawkinsMMGrimaudEHardimanCDialloIVassalGBessaECampbellSPanisXDaly-SchveitzerNLagrangeJLZuckerJMEschwègeFChavaudraJLemerleJ. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumors during childhood. Int J Cancer1998; 77: 370–7.
78.
TroisiRMastersMNJoshipuraKDouglassCColeBFHooverRN. Perinatal factors, growth and development, and osteosarcoma risk. Br J Cancer2006; 95: 1603–7.
79.
YangJCogdellDYangDHuLLiHZhengHDuXPangYTrentJChenKZhangW. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett2010; 291: 31–8.
80.
KurekKCDel MareSSalahZAbdeenSSadiqHLeeS-HGaudioEZanesiNJonesKBDeYoungBAmirGGebhardtMWarmanMSteinGSSteinJLLianJBAqeilanRI. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res2010; 70: 5577–86.
81.
DinizMGBorgesERPimentaFJDe Mesquita NettoACDe MarcoLGomezRSGomesCC. Evidence of molecular alterations in the tumor suppressor gene WWOX in benign and malignant bone related lesions of the jaws. Oncol Rep2011; 25: 499–502.
82.
Del MareSKurekKCSteinGSLianJBAqeilanRI. Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma. Am J Cancer Res2011; 1: 585–94.
83.
AbdeenSKDel MareSHussainSAbu-RemailehMSalahZHaganJRawahnehMPuXARussellSSteinJLSteinGSLianJBAqeilanRI. Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype. J Cell Physiol2013; 228: 1377–82.
84.
Ludes-MeyersJHKilHParker-ThornburgJKusewittDFBedfordMTAldazCM. Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One2009; 4: e7775–e7775.
85.
LiCShiXZhouGLiuXWuSZhaoJ. The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma. Front Biosci Landmark Ed2013; 18: 1384–91.
KimCShinEHongSChonHJKimHRAhnJRHongMHYangWIRohJKRhaSY. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat2009; 41: 138–44.
88.
ParkH-RJungWWBacchiniPBertoniFKimY-WParkY-K. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract2006; 202: 509–15.
89.
SalahZAqeilanRHuebnerK. WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol Lond Engl2010; 6: 249–59.
90.
SalahZBar-magTKohnYPichiorriFPalumboTMelinoGAqeilanRI. Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy. Cell Death Dis2013; 4: e480–e480.
91.
RuddonRW. The epidemiology of human cancer. Cancer biology, 4th ed. Oxford; New York: Oxford University Press, 2007, pp. 62–113.
92.
WinardiWTsaiC-YChenW-TTsaiH-PChungC-LLohJ-KChaiCYKwanAL. Reduced WWOX protein expression in human astrocytoma. Neuropathology2013; 33: 621–7.
ChiangM-FChouP-YWangW-JSzeC-IChangN-S. Tumor suppressor WWOX and p53 alterations and drug resistance in glioblastomas. Front Oncol2013; 3: 43–43.
95.
ChiangM-FYehS-TLiaoH-FChangN-SChenY-J. Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. Biomed Pharmacother2012; 66: 433–8.
96.
OlarAAldapeKD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol2014; 232: 165–77.
97.
KoslaKPluciennikEKurzykAJesionek-KupnickaDKordekRPotemskiPBednarekAK. Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. J Neurooncol2011; 101: 207–13.
98.
Yu K, Fan J, Ding X, Li C, Wang J, Xiang Y, Wang QS. Association study of a functional copy number variation in the WWOX gene with risk of gliomas among Chinese people. Int J Cancer 2014;135:1687–91.
99.
ChiangM-FChenS-TLoC-PSzeC-IChangN-SChenY-J. Expression of WW domain-containing oxidoreductase WOX1 in human nervous system tumors. Anal Cell Pathol (Amst)2013; 36: 133–47.
100.
MallaretMSynofzikMLeeJSagumCAMahajnahMSharkiaRDrouotNRenaudMKleinFAAnheimMTranchantCMignotCMandelJLBedfordMBauerPSalihMASchüleRSchölsLAldazCMKoenigM. The tumor suppressor gene WWOX is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation. Brain J Neurol2014; 137: 411–9.
101.
Abdel-SalamGThoenesMAfifiHHKörberFSwanDBolzHJ. The supposed tumor suppressor gene WWOX is mutated in an early lethal microcephaly syndrome with epilepsy, growth retardation and retinal degeneration. Orphanet J Rare Dis2014; 9: 12–12.
102.
IshiiHVecchioneAFurukawaYSutheesophonKHanS-YDruckTKurokiTTrapassoFNishimuraMSaitoYOzawaKCroceCMHuebnerKFurukawaY. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res2003; 1: 940–7.
103.
YakicierMCLegoixPVauryCGressinLTubacherECapronFBayerJDegottCBalabaudCZucman-RossiJ. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene2001; 20: 5232–8.
104.
IshiiHFurukawaY. Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol2004; 79: 238–42.
105.
Geurts van KesselA. New insights and clinical advancements in cellular oncology. Cell Oncol (Dordr)2012; 35: 139–47.
106.
ChenXZhangHLiPYangZQinLMoW. Gene expression of WWOX, FHIT and p73 in acute lymphoblastic leukemia. Oncol Lett2013; 6: 963–9.
107.
CuiZLinDChengFLuoLKongLXuJHuJLanF. The role of the WWOX gene in leukemia and its mechanisms of action. Oncol Rep2013; 29: 2154–62.
108.
Skotnicka-KlonowiczGRieskePBartkowiakJSzymik-KantorowiczSDaszkiewiczPDebiec-RychterM. 16q heterozygosity loss in Wilms’ tumour in children and its clinical importance. Eur J Surg Oncol2000; 26: 61–6.
109.
NowakowskaMPłuciennikEWujcickaWISitkiewiczAKazanowskaBZielińskaEBednarekAK. The correlation analysis of WWOX expression and cancer related genes in neuroblastoma—a real time RT-PCR study. Acta Biochim Pol2014; 61: 91–7.
110.
PłuciennikENowakowskaMWujcickaWISitkiewiczAKazanowskaBZielińskaEBednarekAK. Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis. Oncol Rep2012; 28: 1417–22.
